Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial - PubMed
3 hours ago
- #rivaroxaban
- #myocardial infarction
- #clinical trial
- The APERITIF trial investigated the effect of adding low-dose rivaroxaban to dual antiplatelet therapy (DAPT) in preventing left ventricular (LV) thrombus after anterior ST-segment elevation myocardial infarction (STEMI).
- 560 patients with anterior STEMI were randomized to receive either DAPT plus rivaroxaban (2.5 mg twice daily for 4 weeks) or DAPT alone.
- At 1 month, LV thrombus was detected in 13.7% of the rivaroxaban group and 16.6% of the DAPT alone group, with no statistically significant difference (P = .34).
- No significant differences were observed in major adverse cardiovascular events or major bleeding events between the two groups.
- Minor bleeding events were more frequent in the rivaroxaban group (16.4% vs. 7.2%).
- The study concluded that low-dose rivaroxaban did not significantly reduce LV thrombus formation but increased minor bleeding, suggesting cautious interpretation due to limited study power.